• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Senseonics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    5/4/26 4:01:51 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care
    Get the next $SENS alert in real time by email
    false 0001616543 0001616543 2026-05-01 2026-05-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): May 1, 2026

     

    SENSEONICS HOLDINGS, INC.
    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-37717   47-1210911
    (State or Other
    Jurisdiction of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    20451 Seneca Meadows Parkway
    Germantown, MD 20876-7005
    (Address of Principal Executive Office) (Zip Code)

     

    Registrant's telephone number, including area code: (301) 515-7260

     

    Not Applicable

    Former name or former address, if changed since last report

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, $0.001 par value SENS Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On May 1, 2026, Senseonics Holdings, Inc. (the “Company”) together with several of its wholly-owned subsidiaries (collectively, “Senseonics”) entered into a Second Amendment to Loan and Security Agreement (the “Second Amendment”) with the several financial institutions or entities party thereto (collectively, the “Lenders”) and Hercules Capital, Inc., a Maryland corporation (the “Agent”), in its capacity as administrative agent and collateral agent for itself and the Lenders, which further amends the Company’s existing Loan and Security Agreement, dated as of September 8, 2023, as previously amended by the First Amendment to Loan and Security Agreement, dated as of September 3, 2025 (as further amended, the “Amended Loan Agreement”), by and among Senseonics, certain of the Lenders and the Agent.

     

    Pursuant to the Amended Loan Agreement, the Lenders have agreed to make available to Senseonics up to $140.0 million in senior secured term loans, consisting of (i) an initial term loan of $35.0 million, which was previously funded, (ii) a term loan of $10.0 million to be funded at the closing of the Second Amendment (the “Tranche 2 Loan”), (iii) four additional tranches of term loans in the amounts of up to $10.0 million (the “Tranche 3A Loan”), $10.0 million (the “Tranche 3B Loan”), $15.0 million (the “Tranche 4 Loan”) and uncommitted $60.0 million (the “Tranche 5 Loan”), respectively, which will become available to Senseonics upon Senseonics’ satisfaction of certain terms and conditions set forth in the Amended Loan Agreement. The loans under the Amended Loan Agreement mature on September 3, 2029 (the “Maturity Date”). The Company expects both the Tranche 2 Loan and Tranche 3A Loan to be funded at the closing of the Second Amendment, which is scheduled to be May 6, 2026 (the “Amendment Closing Date”), subject to customary closing conditions.

     

    The loans under the Amended Loan Agreement bear interest at an annual rate equal to the greater of (i) the prime rate as reported in The Wall Street Journal plus 2.40% and (ii) 9.90%. Borrowings under the Amended Loan Agreement are repayable in monthly interest-only payments through (a) October 1, 2028 and (b) if Senseonics satisfies the 2025 Tranche 3B Milestone (as defined in the Amended Loan Agreement), the Maturity Date. After the interest-only payment period, borrowings under the Amended Loan Agreement are repayable in equal monthly payments of principal and accrued interest until the Maturity Date.

     

    At Senseonics’ option, Senseonics may prepay all or any portion of the outstanding borrowings under the Amended Loan Agreement, subject to a prepayment fee equal to (a) 3.0% of the principal amount being prepaid if the prepayment occurs within one year of the Amendment Closing Date, (b) 2.0% of the principal amount being prepaid if the prepayment occurs during the second year following the Amendment Closing Date, and (c) 1.00% of the principal amount being prepaid if the prepayment occurs more than two years after the Amendment Closing Date and prior to the Maturity Date. In addition, a $100,000 facility fee and a $100,000 amendment fee are payable on the Amendment Closing Date and Senseonics will pay additional facility fees in the amount of 0.50% of any drawn Tranche 3B Loan, or in the amount of 1.00% of any drawn Tranche 4 Loan or Tranche 5 Loan.

     

    Pursuant to the Amended Loan Agreement, the Company agreed to issue additional warrants (the “Additional Warrants”) in substantially the same form as the warrants issued in connection with the initial term loan upon the funding of the Tranche 2 Loan, Tranche 3A Loan, Tranche 3B Loan, Tranche 4 Loan and Tranche 5 Loan. The Additional Warrants may be exercised through the earlier of (i) the seventh anniversary of the applicable issuance date and (ii) the consummation of certain acquisition transactions involving the Company, as set forth in such Additional Warrants. The number of shares of the Company’s common stock for which the Additional Warrants are exercisable and the associated exercise price are subject to certain customary proportional adjustments for fundamental events, including stock splits and reverse stock splits, as set forth in the Additional Warrants. The Additional Warrants would be exercisable for an aggregate number of shares of the Company’s common stock equal to 2.0% of the funded loan amount divided by the exercise price equal to the three-day volume-weighted average price of the Company’s common stock prior to the issuance date of such Additional Warrants.

     

    The foregoing descriptions of the Amended Loan Agreement and the Additional Warrants contained herein do not purport to be complete and are qualified in their entirety by reference to the full text of the Amended Loan Agreement, which is expected to be filed at the time of the Company’s Quarterly Report on 10-Q for the second quarter 2026, and the form of Warrant Agreement, which was filed as Exhibit 10.1 to the Form 8-K filed by the Company on September 11, 2023, and incorporated herein by reference.

     

     

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information included under Item 1.01 above is incorporated by reference into this Item 2.03.

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements include statements related to the anticipated closing of the Amended Loan Agreement, and the availability of funding of future tranches of term loans under the Amended Loan Agreement. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including the uncertainties related to the Company’s ability to satisfy milestones for additional borrowing under the Amended Loan Agreement and compliance with covenants thereunder, market conditions and such other risks and uncertainties described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 2, 2026, and other filings the Company makes with the SEC from time to time. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Current Report on Form 8-K. The Company undertakes no duty to update such information except as required under applicable law.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1   Form of Warrant (incorporated herein by reference to Exhibit 10.2 the Company’s Current Report on Form 8-K filed with the SEC on September 11, 2023).
    104*   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    * Filed herewith.
       
    ** Furnished herewith

     

      # Certain information has been omitted from this document in accordance with Regulation S-K, Item 601(b)(10).

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 4, 2026 SENSEONICS HOLDINGS, INC.
     
      By: /s/ Rick Sullivan
      Name: Rick Sullivan
      Title: Chief Financial Officer

     

     

     

    Get the next $SENS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SENS

    DatePrice TargetRatingAnalyst
    10/21/2025$9.00Hold
    Stifel
    8/27/2025$1.50Overweight
    Barclays
    7/15/2025$1.25Buy
    TD Cowen
    6/2/2025$1.10Buy
    H.C. Wainwright
    4/10/2025$2.00Outperform
    Mizuho
    7/19/2023$0.50Underperform
    Jefferies
    8/19/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SENS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Kaufman Francine was granted 63,177 shares, increasing direct ownership by 54% to 181,067 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/21/26 5:42:42 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    GC & Corp. Development Advisor Horton Kenneth L was granted 157,943 shares, increasing direct ownership by 115% to 295,057 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/21/26 5:41:33 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Jain Mukul was granted 270,759 shares, increasing direct ownership by 110% to 517,057 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/21/26 5:40:28 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Senseonics with a new price target

    Stifel resumed coverage of Senseonics with a rating of Hold and set a new price target of $9.00

    10/21/25 7:22:14 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Senseonics with a new price target

    Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50

    8/27/25 8:26:33 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Senseonics with a new price target

    TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25

    7/15/25 8:44:36 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roeder Douglas A bought $126,134 worth of shares (22,686 units at $5.56), increasing direct ownership by 19% to 144,635 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/13/26 4:15:05 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Roeder Douglas A bought $100,275 worth of shares (17,500 units at $5.73), increasing direct ownership by 17% to 119,731 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    3/16/26 10:44:45 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    President and CEO Goodnow Timothy T bought $99,733 worth of shares (17,225 units at $5.79), increasing direct ownership by 3% to 651,243 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    3/16/26 10:44:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026

    GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana. Senseonics will be hosting an analyst event to discuss the Eversense 365 platform, as well as an oral presentation on the ADA program discussing real world evidence of the world's first and only one year CGM system. Analyst Event DetailsSenseonics

    6/1/26 8:00:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results

    Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe Raised $100M+ in equity and debt financing to support commercial strategy and pipeline GERMANTOWN, MD., May 07, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced first quarter 2026 financial results and provided a business update

    5/7/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of $92 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Senseonics sold 10,400,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 2,400,000 additional shares of common stock, and 8,000,000 pre-funded warrants. The shares of c

    5/4/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    SEC Filings

    View All

    SEC Form SD filed by Senseonics Holdings Inc.

    SD - Senseonics Holdings, Inc. (0001616543) (Filer)

    6/1/26 5:07:59 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Senseonics Holdings Inc.

    S-8 - Senseonics Holdings, Inc. (0001616543) (Filer)

    5/20/26 4:51:58 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    5/20/26 4:29:06 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $SENS
    Financials

    Live finance-specific insights

    View All

    Senseonics Holdings, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call for May 7, 2026 at 4:30 P.M. Eastern Time

    GERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will hold a conference call to review the Company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseon

    5/1/26 9:10:31 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update. Recent Highlights & Accomplishments Generated fourth quarter 2025 revenue of $14.3 million, an increase

    3/2/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update

    Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year 2025 financial results on March 2, 2026 GERMANTOWN, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for the fourth quarter of 2025 and provided a general business update. Recent Highlights & Accomplishments Generated preliminary unaudite

    1/12/26 8:00:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    2/13/24 5:13:59 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    7/7/23 4:35:55 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Senseonics Holdings Inc.

    SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)

    4/10/23 5:10:45 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care